McMillan Advises Mallinckrodt plc on its Sale of Therakos

On December 4, 2024, Mallinckrodt plc (“Mallinckrodt”) completed its previously announced sale of its Therakos business to CVC Capital Partners (“CVC”). The investment from in Therakos from CVC will provide the resources and expertise to further develop the business and its services which improve the lives of patients.

Therakos is the leading company in Extracorporeal Photopheresis (ECP) delivery systems for autologous immunomodulatory therapy. With approvals for use in the U.S., Canada, Europe, Japan, Australia, Latin America and South Korea, the Therakos’ systems are the platform-of-choice among healthcare providers and patients to treat a range of immune-related diseases.

CVC is a leading global private markets manager.

Mallinckrodt is a global speciality pharmaceutical company.

Working alongside A&O Shearman, McMillan acted as Canadian legal support to Mallinckrodt in connection this this cross-border transaction. Tess Dimroci and David Dunlop led the national and multidisciplinary team which included Ted Thiessen, Jamie Wilks, Paul Boshyk, Janine MacNeil, and Joshus Chad.

As a national business law firm with exceptional capabilities to lead businesses through cross-border transactions and investments into Canada and within multifaceted regulatory regimes, McMillan provides real-time business solutions to our clients. Our legal teams are skilled at structuring and closing complex deals in Canada, the US and internationally and in providing innovative transactional advice and solutions. Our understanding of business imperatives and our relationships with regulators help our clients stay ahead.